On January 22, 2026, the 2025 Huagai Healthcare Fund Annual Investor Conference, themed "Sunward Blossoms Herald Spring" and hosted by Huagai Capital Co., Ltd., grandly opened at the Yantai Haijing Building Conference Center. Nearly 270 industry leaders and elites from top research institutions, medical enterprises, and investment institutions gathered in the harbor city to explore new opportunities in the pharmaceutical industry and witness the implementation of several major collaborations. The atmosphere was electric, and the response was overwhelmingly positive.

The conference featured a star-studded lineup. Heavyweight guests including Xu Xiaolin, Founder and Chairman of Huagai Capital; Zhou Xi, Global Managing Partner of McKinsey & Company; Ji Linong, Director of the Endocrinology Department at Peking University People's Hospital; and Zhang Lianshan, Director and Executive Vice President of Jiangsu Hengrui Medicine Co., Ltd., were all in attendance to share in this grand event. It was not only a feast of ideas but also a top-tier collision of resources. Participating guests engaged in profound dialogues on cutting-edge topics such as global biomedical outlooks, macroeconomic trend analysis, the commercial closed-loop for innovative drugs, and the booming weight-loss track, charting the course for the industry's future development.

During the interactive sessions, guests took part in summit dialogues on the "momentum of pharmaceutical innovation," "pipeline breakthroughs and the commercial closed-loop," and the popular "weight-loss track." The atmosphere was rich with exchange and intense debate. From macro strategies to clinical practice, and from global perspectives to China's opportunities, the discussions delivered a deeply insightful brainstorm that resonated powerfully with the audience.

The conference was punctuated by numerous highlights and fruitful outcomes. A grand signing ceremony was held, where Yantai Guofeng Group and Huagai Capital entered into a deep strategic cooperation agreement. Additionally, the "Digital Decoding of Immunity" project was successfully signed and officially settled in the park. This series of agreements not only showcased the robust investment strength and convening power of Huagai Healthcare Fund but also injected powerful momentum into the high-quality development of Yantai's biomedical industry.

The successful hosting of this conference sounded the assembly call for pharmaceutical innovation and development in 2026. It not only demonstrated the investment prowess and industry influence of Huagai Healthcare Fund but also infused new vitality into the growth of Yantai's biomedical sector. Moving forward, Huagai Healthcare Fund will continue to join hands with its partners, leveraging the industrial advantages of Blue Pharma Valley · Life Island, to pioneer and innovate, jointly promoting the vigorous development of Yantai's biomedical industry.